Consumer willingness to pay for a hypothetical Zika vaccine in Brazil

Roberto Lúcio Muniz Júnior, Isabella Piassi Godói, Edna Afonso Reis, Marina Morgado Garcia, Augusto GUERRA Jnr, Brian Godman, Cristina Mariano Ruas Brandão

Research output: Contribution to conferencePoster

2 Downloads (Pure)

Abstract

Introduction: Zika virus is a newly emerging infection associated with increasingly large outbreaks especially in countries such as Brazil where an estimated 326,224 cases were confirmed between 2015 and 2018. Common symptoms associated with Zika include headache, conjunctivitis, fever, erythema, myalgia, vomiting, diarrhea, and abdominal pain. However, the symptoms are usually self-limiting and last on average for 4 to 7 days, with patients typically not accessing the public healthcare system (SUS). In severe cases, symptoms include neurological disorders and neonatal malformations. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. However, this has to be balanced against continuing costs to control this and other vector borne diseases. Consequently, information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help with price setting discussions in Brazil starting with the private market before being considered within SUS. Methods: A cross-sectional study was conducted among residents in one of the main provinces of Brazil (Minas Gerais) regarding their WTP for a hypothetical Zika Vaccine with agreed characteristics. This included a mean effective protection of 80%, with the possibility of some local and systemic side-effects. The discussed price was US$ 56.41(180.00 BRL) per vaccination as this figure was utilized in a previous WTP study for a dengue vaccine. Results: 517 people were interviewed. However, 30 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), were employed (71.2%), had private health insurance (52.7%), had household incomes above twice the minimum wage (69.8%) and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine was US$31.34 (BRL100.00). Conclusion: WTP research can contribute to decision-making about possible prices alongside other economic criteria once a Zika vaccine becomes available in Brazil alongside other programmes to control the virus.
Original languageEnglish
Number of pages1
Publication statusAccepted/In press - 1 Feb 2019
EventHTAi Cologne, Germany - Cologne, Germany
Duration: 15 Jun 201919 Jun 2019
http://www.htai2019.org/

Conference

ConferenceHTAi Cologne, Germany
CountryGermany
CityCologne
Period15/06/1919/06/19
Internet address

Fingerprint

Brazil
Vaccines
Dengue Vaccines
Disease Vectors
Conjunctivitis
Cost Control
Salaries and Fringe Benefits
Myalgia
Erythema
Health Insurance
Nervous System Diseases
Abdominal Pain
Vomiting
Disease Outbreaks
Headache
Diarrhea
Decision Making
Vaccination
Fever
Cross-Sectional Studies

Keywords

  • Zika virus
  • Brazil
  • Zika virus vaccine

Cite this

Muniz Júnior, R. L., Godói, I. P., Reis, E. A., Garcia, M. M., GUERRA Jnr, A., Godman, B., & Brandão, C. M. R. (Accepted/In press). Consumer willingness to pay for a hypothetical Zika vaccine in Brazil. Poster session presented at HTAi Cologne, Germany, Cologne, Germany.
Muniz Júnior, Roberto Lúcio ; Godói, Isabella Piassi ; Reis, Edna Afonso ; Garcia, Marina Morgado ; GUERRA Jnr, Augusto ; Godman, Brian ; Brandão, Cristina Mariano Ruas. / Consumer willingness to pay for a hypothetical Zika vaccine in Brazil. Poster session presented at HTAi Cologne, Germany, Cologne, Germany.1 p.
@conference{c72c7de5c6a841979688f380e5037b6f,
title = "Consumer willingness to pay for a hypothetical Zika vaccine in Brazil",
abstract = "Introduction: Zika virus is a newly emerging infection associated with increasingly large outbreaks especially in countries such as Brazil where an estimated 326,224 cases were confirmed between 2015 and 2018. Common symptoms associated with Zika include headache, conjunctivitis, fever, erythema, myalgia, vomiting, diarrhea, and abdominal pain. However, the symptoms are usually self-limiting and last on average for 4 to 7 days, with patients typically not accessing the public healthcare system (SUS). In severe cases, symptoms include neurological disorders and neonatal malformations. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. However, this has to be balanced against continuing costs to control this and other vector borne diseases. Consequently, information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help with price setting discussions in Brazil starting with the private market before being considered within SUS. Methods: A cross-sectional study was conducted among residents in one of the main provinces of Brazil (Minas Gerais) regarding their WTP for a hypothetical Zika Vaccine with agreed characteristics. This included a mean effective protection of 80{\%}, with the possibility of some local and systemic side-effects. The discussed price was US$ 56.41(180.00 BRL) per vaccination as this figure was utilized in a previous WTP study for a dengue vaccine. Results: 517 people were interviewed. However, 30 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2{\%}), were employed (71.2{\%}), had private health insurance (52.7{\%}), had household incomes above twice the minimum wage (69.8{\%}) and did not have Zika (96.9{\%}). The median individual maximum WTP for this hypothetical Zika vaccine was US$31.34 (BRL100.00). Conclusion: WTP research can contribute to decision-making about possible prices alongside other economic criteria once a Zika vaccine becomes available in Brazil alongside other programmes to control the virus.",
keywords = "Zika virus, Brazil, Zika virus vaccine",
author = "{Muniz J{\'u}nior}, {Roberto L{\'u}cio} and God{\'o}i, {Isabella Piassi} and Reis, {Edna Afonso} and Garcia, {Marina Morgado} and {GUERRA Jnr}, Augusto and Brian Godman and Brand{\~a}o, {Cristina Mariano Ruas}",
year = "2019",
month = "2",
day = "1",
language = "English",
note = "HTAi Cologne, Germany ; Conference date: 15-06-2019 Through 19-06-2019",
url = "http://www.htai2019.org/",

}

Muniz Júnior, RL, Godói, IP, Reis, EA, Garcia, MM, GUERRA Jnr, A, Godman, B & Brandão, CMR 2019, 'Consumer willingness to pay for a hypothetical Zika vaccine in Brazil' HTAi Cologne, Germany, Cologne, Germany, 15/06/19 - 19/06/19, .

Consumer willingness to pay for a hypothetical Zika vaccine in Brazil. / Muniz Júnior, Roberto Lúcio ; Godói, Isabella Piassi; Reis, Edna Afonso ; Garcia, Marina Morgado; GUERRA Jnr, Augusto; Godman, Brian; Brandão, Cristina Mariano Ruas.

2019. Poster session presented at HTAi Cologne, Germany, Cologne, Germany.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Consumer willingness to pay for a hypothetical Zika vaccine in Brazil

AU - Muniz Júnior, Roberto Lúcio

AU - Godói, Isabella Piassi

AU - Reis, Edna Afonso

AU - Garcia, Marina Morgado

AU - GUERRA Jnr, Augusto

AU - Godman, Brian

AU - Brandão, Cristina Mariano Ruas

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Zika virus is a newly emerging infection associated with increasingly large outbreaks especially in countries such as Brazil where an estimated 326,224 cases were confirmed between 2015 and 2018. Common symptoms associated with Zika include headache, conjunctivitis, fever, erythema, myalgia, vomiting, diarrhea, and abdominal pain. However, the symptoms are usually self-limiting and last on average for 4 to 7 days, with patients typically not accessing the public healthcare system (SUS). In severe cases, symptoms include neurological disorders and neonatal malformations. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. However, this has to be balanced against continuing costs to control this and other vector borne diseases. Consequently, information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help with price setting discussions in Brazil starting with the private market before being considered within SUS. Methods: A cross-sectional study was conducted among residents in one of the main provinces of Brazil (Minas Gerais) regarding their WTP for a hypothetical Zika Vaccine with agreed characteristics. This included a mean effective protection of 80%, with the possibility of some local and systemic side-effects. The discussed price was US$ 56.41(180.00 BRL) per vaccination as this figure was utilized in a previous WTP study for a dengue vaccine. Results: 517 people were interviewed. However, 30 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), were employed (71.2%), had private health insurance (52.7%), had household incomes above twice the minimum wage (69.8%) and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine was US$31.34 (BRL100.00). Conclusion: WTP research can contribute to decision-making about possible prices alongside other economic criteria once a Zika vaccine becomes available in Brazil alongside other programmes to control the virus.

AB - Introduction: Zika virus is a newly emerging infection associated with increasingly large outbreaks especially in countries such as Brazil where an estimated 326,224 cases were confirmed between 2015 and 2018. Common symptoms associated with Zika include headache, conjunctivitis, fever, erythema, myalgia, vomiting, diarrhea, and abdominal pain. However, the symptoms are usually self-limiting and last on average for 4 to 7 days, with patients typically not accessing the public healthcare system (SUS). In severe cases, symptoms include neurological disorders and neonatal malformations. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. However, this has to be balanced against continuing costs to control this and other vector borne diseases. Consequently, information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help with price setting discussions in Brazil starting with the private market before being considered within SUS. Methods: A cross-sectional study was conducted among residents in one of the main provinces of Brazil (Minas Gerais) regarding their WTP for a hypothetical Zika Vaccine with agreed characteristics. This included a mean effective protection of 80%, with the possibility of some local and systemic side-effects. The discussed price was US$ 56.41(180.00 BRL) per vaccination as this figure was utilized in a previous WTP study for a dengue vaccine. Results: 517 people were interviewed. However, 30 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), were employed (71.2%), had private health insurance (52.7%), had household incomes above twice the minimum wage (69.8%) and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine was US$31.34 (BRL100.00). Conclusion: WTP research can contribute to decision-making about possible prices alongside other economic criteria once a Zika vaccine becomes available in Brazil alongside other programmes to control the virus.

KW - Zika virus

KW - Brazil

KW - Zika virus vaccine

UR - http://www.HTAi2019.org

M3 - Poster

ER -

Muniz Júnior RL, Godói IP, Reis EA, Garcia MM, GUERRA Jnr A, Godman B et al. Consumer willingness to pay for a hypothetical Zika vaccine in Brazil. 2019. Poster session presented at HTAi Cologne, Germany, Cologne, Germany.